Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Sales reflect continued strong growth in oncology and vaccines
Open a printable version of this pageEmail the URL of this page to a friend
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Subscribe To Our Newsletter & Stay Updated
